Waters

Thursday, October 27, 2022 at 11 am EDT | 6 am PDT | 1 pm GMT | 2 pm CET Learn about the latest advancements in glycan analysis and how to address challenges of glycan analysis of new modalities.

Tuesday, September 20, 2022 at 11 AM EST During chromatographic analysis of complex biotherapeutics, analytes may contain electron-rich functional groups, which have an affinity to metal surfaces and may cause issues such as poor peak shape. Join our webinar to learn how Waters addresses these challenges.

Thursday, June 23, 2022 at 10am ET | 3pm BST | 4pm CEST Join us on June 23 to learn about QC Analysis of Oligonucleotide Therapeutics. One Platform Method for Determining Identity, Purity, and Quantity.

Thursday, March 24, 2022 at 11am EST | 10am CST | 8am PST Advancing size-exclusion chromatography through recent developments in particle technology and hydrophilic surfaces.

See how implementing an enhanced approach, like Analytical Quality by Design (AQbD), for method development can help you to access high quality, reportable data.

This case study determines the adoption of Waters ACQUITY UPLC and ACQUITY QDa™ technology in contributing to the success of independent pharmaceutical service provider Chromicent, by providing more information faster and earlier in the method development process.

In this work, an UltraPerformance Liquid Chromatography method was developed for the analysis of Valsartan and a mixture of six genotoxic impurities using the Analytical Quality by Design (AQbD) approach. Findings indicated that using the AQbD approach and automated software helps gain a deep knowledge about the method and as a result, increases method robustness and reproducibility.

Learn how Hovione, a global CDMO, has determined that the combination of Waters instrumentation and AQbD is a powerful strategy for method development that leads to better, faster, greener analytical methods, enables resource optimization, and more.

Using the Analytical Quality by Design (AQbD) approach, an Ultra High Performance Liquid Chromatography method was developed for the analysis of a mixture of metal chelating and non-chelating compounds. DryLab, Empower, and Waters systems were used to automate the method development process.

Analytical method performance is critical to ensure the quality, safety, and efficacy of pharmaceutical products. Two of the most commonly used ones are One Factor at a Time (OFAT) and Analytical Quality by Design (AQbD). In this work, a robust method for budesonide, formoterol, and related compounds was developed using a Quality by Design approach on an ACQUITY UPLC H-Class PLUS System running Empower 3 and Fusion Software.

Chromatographic methods developed to analyze pharmaceutical compounds must distinguish low-level impurities before they reach alert/action levels. Parameters such as retention, peak shape, and sensitivity are very important to successfully accomplish this. Read this app note to learn more about MaxPeak Premier Technology.

This white paper describes the use of Empower™ 3 Control Charts to facilitate the continued procedure performance verification stage of the analytical procedure lifecycle approach.

Modern approaches to analytical procedure development such as Analytical Quality-by-Design (AQbD) focus on the reliability and accuracy of the final result, encouraging Analytical Developers to understand how aspects of sampling, storage, sample preparation, personnel training, instrument parameters, and data handling might affect result reliability. Find out more about AQbD and the best tools to design and develop fit-for-purpose methods.

This infographic demonstrates about Waters’ products, support, training, and expertise for a seamless Analytical Quality by Design (AQbD) implementation in your lab.

*Thursday, March 25, 2021 at 10am EDT| 7am PDT| 2pm GMT| 3pm CET* Join us to learn how to address challenges with screening protein complexes using hydrogen–deuterium exchange and cyclic ion-mobility MS. *On demand available after final airing until March 25, 2022*

***Live: Friday, November 20, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET***Chemical characterization of medical device materials within a risk management process, addressed in ISO 10993 Part 18, was significantly revised in 2020. Part of this critical standard is to ascertain the extractables and leachables from a medical device to enable the estimation and control of biological risks. Join us for this webcast to learn about an LC–MS workflow to help address this challenge.***On demand available after final airing until NOV. 20, 2021***